US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

37.31

+1.042.87%

Post-market: 36.76-0.5500-1.47%19:30 EDT

Volume:691.82K

Turnover:25.78M

Market Cap:2.61B

PE:-12.23

High:38.13

Open:36.27

Low:35.70

Close:36.27

52wk High:38.13

52wk Low:20.65

Shares:69.86M

Float Shares:43.70M

Volume Ratio:1.03

T/O Rate:1.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.0508

EPS(LYR):-3.4871

ROE:-70.46%

ROA:-42.32%

PB:7.43

PE(LYR):-10.70

Loading ...

Overview Company News Filings

Pharvaris NV director Elisabeth Bjork files initial beneficial ownership statement

Pharvaris NV CFO and CLO David W. Nassif files initial beneficial ownership statement

Pharvaris NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Lu Peng

Pharvaris NV Director Viviane Monges Files Initial Beneficial Ownership Statement

Pharvaris NV CEO Berndt Modig files initial beneficial ownership statement

Is New HAE Patient-Reported Outcome Study Altering The Investment Case For Pharvaris’ Deucrictibant (PHVS)?

Simply Wall St.

Pharvaris (PHVS) Receives a Buy from Morgan Stanley

Pharvaris reports results from study of patient experience during HAE attacks

Pharvaris real-world study validates PGI and AMRA patient-reported outcome measures for acute HAE attacks

Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)

Can Pharvaris (PHVS) Turn Deucrictibant’s Phase 2 Extension Data Into a Durable Franchise Advantage?

Simply Wall St.

Pharvaris' Deucrictibant Presents Opportunity in Hereditary Angioedema Market, RBC Says

MT Newswires Live

RBC Initiates Pharvaris at Outperform, Speculative Risk With $52 Price Target

MT Newswires Live

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pharvaris (PHVS) and Cryo-Cell International (CCEL)

Pharvaris Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Pharvaris (PHVS) Valuation Check After Positive Deucrictibant Phase 2 And RAPIDe 3 Results

Simply Wall St.

Pharvaris reports Phase 3 RAPIDe-3 success for deucrictibant in hereditary angioedema attacks

BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million

Morgan Stanley Remains a Buy on Pharvaris (PHVS)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PHVS/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PHVS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PHVS\",,,,,undefined,":{"symbol":"PHVS","market":"US","secType":"STK","nameCN":"Pharvaris N.V.","latestPrice":37.31,"timestamp":1787601600000,"preClose":36.27,"halted":0,"volume":691824,"hourTrading":{"tag":"盘后","latestPrice":36.76,"preClose":37.31,"latestTime":"19:30 EDT","volume":6404,"amount":238877.04,"timestamp":1787614203692,"change":-0.55,"changeRate":-0.014741,"amplitude":0.014741},"delay":0,"changeRate":0.028673835125448004,"floatShares":43698700,"shares":69863685,"eps":-3.0508,"marketStatus":"Closed","change":1.04,"latestTime":"08-24 16:00:00 EDT","open":36.27,"high":38.13,"low":35.7,"amount":25780021.611456,"amplitude":0.066998,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.0508,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":36.27,"preHourTrading":{"tag":"盘前","latestPrice":36.65,"preClose":36.27,"latestTime":"09:28 EDT","volume":455,"amount":16346.853249999998,"timestamp":1787578080045,"change":0.38,"changeRate":0.010477,"amplitude":0.021781},"postHourTrading":{"tag":"盘后","latestPrice":36.76,"preClose":37.31,"latestTime":"19:30 EDT","volume":6404,"amount":238877.04,"timestamp":1787614203692,"change":-0.55,"changeRate":-0.014741,"amplitude":0.014741},"volumeRatio":1.032085,"impliedVol":1.0209,"impliedVolPercentile":0.8269},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PHVS\",,,,,undefined,":{"symbol":"PHVS","floatShares":43698700,"roa":"-42.32%","roe":"-70.46%","lyrEps":-3.487143,"volumeRatio":1.032085,"shares":69863685,"dividePrice":0,"high":38.13,"amplitude":0.066998,"preClose":36.27,"low":35.7,"week52Low":20.65,"pbRate":"7.43","week52High":38.13,"institutionHeld":0,"latestPrice":37.31,"eps":-3.0508,"divideRate":0,"volume":691824,"delay":0,"ttmEps":-3.0508,"open":36.27,"prevYearClose":27.75,"prevWeekClose":36.27,"prevMonthClose":32.62,"prevQuarterClose":34.58,"fiveDayClose":35.32,"twentyDayClose":33.97,"sixtyDayClose":29.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PHVS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"PHVS","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"pre","actualEps":-0.81},{"market":"US","date":"2026-05-12","symbol":"PHVS","fiscalQuarterEnding":"2026/03","expectedEps":-0.76,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.7},{"market":"US","date":"2026-04-02","symbol":"PHVS","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1775102400000,"reportTimeType":"pre","actualEps":-0.84},{"market":"US","date":"2025-11-12","symbol":"PHVS","fiscalQuarterEnding":"2025/09","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.7},{"market":"US","date":"2025-08-12","symbol":"PHVS","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.94}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PHVS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PHVS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4667,"buy":0.4667,"hold":0.0667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4667,"analysts":15,"updateTime":1784347200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PHVS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PHVS","date":"2026-08-21","current":-12.229579,"percent":0.133936,"low":-16.528573,"twenty":-12.094187,"median":-8.622235,"eighty":-5.917471,"high":-1.271834,"avg":-8.835814,"sd":3.181652,"marketCap":2554741973},"quantilePoints":[{"date":"2021-08-27","current":-14.6624,"twenty":-41.760653,"median":-21.796739,"eighty":-14.375312,"marketCap":660584144},{"date":"2021-09-03","current":-13.869765,"twenty":-41.690069,"median":-21.159134,"eighty":-14.206363,"marketCap":629774552},{"date":"2021-09-10","current":-14.483783,"twenty":-41.636401,"median":-21.097683,"eighty":-14.200739,"marketCap":654620997},{"date":"2021-09-17","current":-13.408551,"twenty":-41.415194,"median":-19.619941,"eighty":-14.095163,"marketCap":601399913},{"date":"2021-09-24","current":-13.735189,"twenty":-41.105195,"median":-19.412718,"eighty":-13.917369,"marketCap":614535400},{"date":"2021-10-01","current":-13.275187,"twenty":-41.073352,"median":-19.361573,"eighty":-13.752501,"marketCap":588032525},{"date":"2021-10-08","current":-11.567624,"twenty":-40.951984,"median":-19.206349,"eighty":-13.609193,"marketCap":511505475},{"date":"2021-10-15","current":-11.808567,"twenty":-40.76486,"median":-19.158657,"eighty":-13.358075,"marketCap":523431769},{"date":"2021-10-22","current":-11.367098,"twenty":-40.543106,"median":-18.996962,"eighty":-13.26419,"marketCap":505211043},{"date":"2021-10-29","current":-13.069107,"twenty":-40.31092,"median":-18.615071,"eighty":-13.235325,"marketCap":577431375},{"date":"2021-11-05","current":-11.318661,"twenty":-40.118706,"median":-18.174436,"eighty":-12.989342,"marketCap":499744825},{"date":"2021-11-12","current":-12.526544,"twenty":-39.882961,"median":-18.037659,"eighty":-12.809718,"marketCap":547946928},{"date":"2021-11-19","current":-11.924212,"twenty":-39.73926,"median":-17.467833,"eighty":-12.433857,"marketCap":515812193},{"date":"2021-11-26","current":-10.362749,"twenty":-39.575288,"median":-16.707882,"eighty":-12.294384,"marketCap":448064220},{"date":"2021-12-03","current":-11.26034,"twenty":-38.958466,"median":-15.822297,"eighty":-12.166304,"marketCap":485665173},{"date":"2021-12-10","current":-11.449501,"twenty":-38.90261,"median":-15.106412,"eighty":-12.085176,"marketCap":494941179},{"date":"2021-12-17","current":-11.918983,"twenty":-38.786622,"median":-14.824901,"eighty":-12.032102,"marketCap":513493191},{"date":"2021-12-23","current":-12.067526,"twenty":-38.613439,"median":-14.809703,"eighty":-12.04158,"marketCap":521775339},{"date":"2021-12-31","current":-10.970608,"twenty":-38.556139,"median":-14.6624,"eighty":-12.029733,"marketCap":476720453},{"date":"2022-01-07","current":-14.755715,"twenty":-38.260176,"median":-14.556631,"eighty":-12.04158,"marketCap":639381844},{"date":"2022-01-14","current":-13.648303,"twenty":-37.900499,"median":-14.301086,"eighty":-12.059144,"marketCap":595652102},{"date":"2022-01-21","current":-13.462107,"twenty":-37.887735,"median":-14.301086,"eighty":-12.06585,"marketCap":583394522},{"date":"2022-01-28","current":-13.205088,"twenty":-37.172324,"median":-14.201073,"eighty":-12.067932,"marketCap":563186081},{"date":"2022-02-04","current":-13.024782,"twenty":-36.626254,"median":-14.120681,"eighty":-12.079807,"marketCap":569480513},{"date":"2022-02-11","current":-13.759795,"twenty":-36.368387,"median":-14.065459,"eighty":-12.092451,"marketCap":599627533},{"date":"2022-02-18","current":-13.388638,"twenty":-36.150333,"median":-14.023379,"eighty":-12.098608,"marketCap":579750377},{"date":"2022-02-25","current":-13.305926,"twenty":-35.845851,"median":-13.954525,"eighty":-12.116084,"marketCap":572793372},{"date":"2022-03-04","current":-14.115965,"twenty":-35.670778,"median":-13.938377,"eighty":-12.137788,"marketCap":588695097},{"date":"2022-03-11","current":-13.463028,"twenty":-34.421493,"median":-13.892451,"eighty":-12.149516,"marketCap":563186081},{"date":"2022-03-18","current":-14.218002,"twenty":-29.632768,"median":-13.881977,"eighty":-12.157248,"marketCap":600952677},{"date":"2022-03-25","current":-13.943073,"twenty":-26.658074,"median":-13.883771,"eighty":-12.178203,"marketCap":585382238},{"date":"2022-04-01","current":-12.747151,"twenty":-26.362243,"median":-13.880091,"eighty":-12.194172,"marketCap":601209361},{"date":"2022-04-08","current":-13.160374,"twenty":-26.219887,"median":-13.869765,"eighty":-12.198767,"marketCap":611652204},{"date":"2022-04-14","current":-12.64181,"twenty":-26.010325,"median":-13.786628,"eighty":-12.200601,"marketCap":583804624},{"date":"2022-04-22","current":-12.23556,"twenty":-25.770465,"median":-13.764494,"eighty":-12.203958,"marketCap":563581977},{"date":"2022-04-29","current":-12.580911,"twenty":-25.660418,"median":-13.730786,"eighty":-12.217679,"marketCap":566542439},{"date":"2022-05-06","current":-12.310085,"twenty":-25.093495,"median":-13.707219,"eighty":-12.233824,"marketCap":557283119},{"date":"2022-05-13","current":-10.422165,"twenty":-24.148325,"median":-13.655613,"eighty":-12.198139,"marketCap":571878572},{"date":"2022-05-20","current":-10.134271,"twenty":-23.650401,"median":-13.608097,"eighty":-12.152353,"marketCap":563590477},{"date":"2022-05-27","current":-10.266885,"twenty":-23.509475,"median":-13.570194,"eighty":-12.096742,"marketCap":579835143},{"date":"2022-06-03","current":-10.984203,"twenty":-23.463638,"median":-13.4682,"eighty":-12.07039,"marketCap":620612572},{"date":"2022-06-10","current":-12.843347,"twenty":-23.155882,"median":-13.459721,"eighty":-12.067627,"marketCap":712444667},{"date":"2022-06-17","current":-16.528573,"twenty":-22.410251,"median":-13.457335,"eighty":-12.07039,"marketCap":911690477},{"date":"2022-06-24","current":-12.484354,"twenty":-22.307498,"median":-13.442896,"eighty":-12.079819,"marketCap":694210858},{"date":"2022-07-01","current":-14.299351,"twenty":-21.874535,"median":-13.402807,"eighty":-12.068033,"marketCap":784053810},{"date":"2022-07-08","current":-14.094213,"twenty":-21.750061,"median":-13.450115,"eighty":-12.077462,"marketCap":756209125},{"date":"2022-07-15","current":-14.396825,"twenty":-21.331431,"median":-13.463028,"eighty":-12.082165,"marketCap":765820001},{"date":"2022-07-22","current":-13.29424,"twenty":-21.174218,"median":-13.473474,"eighty":-12.092451,"marketCap":716422953},{"date":"2022-07-29","current":-13.469033,"twenty":-21.125909,"median":-13.4682,"eighty":-12.098608,"marketCap":724213762},{"date":"2022-08-05","current":-11.76507,"twenty":-21.101667,"median":-13.459721,"eighty":-12.082165,"marketCap":629895239},{"date":"2022-08-12","current":-10.43948,"twenty":-20.186916,"median":-13.408551,"eighty":-12.055631,"marketCap":564253524},{"date":"2022-08-19","current":-11.581834,"twenty":-19.826532,"median":-13.395996,"eighty":-12.028713,"marketCap":612987524},{"date":"2022-08-26","current":-5.820227,"twenty":-19.515891,"median":-13.372919,"eighty":-11.990749,"marketCap":306659524},{"date":"2022-09-02","current":-5.892736,"twenty":-19.429171,"median":-13.356682,"eighty":-11.943475,"marketCap":311632381},{"date":"2022-09-09","current":-5.834763,"twenty":-19.417564,"median":-13.345814,"eighty":-11.915113,"marketCap":308814429},{"date":"2022-09-16","current":-6.129031,"twenty":-19.393433,"median":-13.317212,"eighty":-11.844209,"marketCap":307945619},{"date":"2022-09-23","current":-5.527907,"twenty":-19.377706,"median":-13.304479,"eighty":-11.805952,"marketCap":269452416},{"date":"2022-09-30","current":-5.268219,"twenty":-19.358729,"median":-13.29424,"eighty":-11.739355,"marketCap":258984966},{"date":"2022-10-07","current":-3.334511,"twenty":-19.313349,"median":-13.281408,"eighty":-11.574558,"marketCap":163427280},{"date":"2022-10-14","current":-3.192899,"twenty":-19.240081,"median":-13.26552,"eighty":-11.519941,"marketCap":155998767},{"date":"2022-10-21","current":-3.776992,"twenty":-19.189017,"median":-13.2607,"eighty":-11.419826,"marketCap":185712818},{"date":"2022-10-28","current":-3.404363,"twenty":-19.175941,"median":-13.241782,"eighty":-11.34035,"marketCap":169704373},{"date":"2022-11-04","current":-2.493588,"twenty":-19.155403,"median":-13.21909,"eighty":-11.293284,"marketCap":123921098},{"date":"2022-11-11","current":-1.962841,"twenty":-19.119693,"median":-13.202703,"eighty":-11.220822,"marketCap":101635560},{"date":"2022-11-18","current":-1.709372,"twenty":-19.040002,"median":-13.169144,"eighty":-11.073401,"marketCap":88804493},{"date":"2022-11-25","current":-1.59989,"twenty":-18.960552,"median":-13.089194,"eighty":-10.924331,"marketCap":83401938},{"date":"2022-12-02","current":-1.271834,"twenty":-18.879299,"median":-13.066255,"eighty":-10.549888,"marketCap":66856614},{"date":"2022-12-09","current":-5.585763,"twenty":-18.659925,"median":-13.055482,"eighty":-10.38824,"marketCap":291250318},{"date":"2022-12-16","current":-4.830297,"twenty":-18.384979,"median":-13.024782,"eighty":-10.32247,"marketCap":253408050},{"date":"2022-12-23","current":-6.371604,"twenty":-18.295522,"median":-12.990589,"eighty":-10.187317,"marketCap":334836503},{"date":"2022-12-30","current":-7.188594,"twenty":-18.170479,"median":-12.982972,"eighty":-10.008759,"marketCap":380112075},{"date":"2023-01-06","current":-7.688928,"twenty":-18.154652,"median":-12.903124,"eighty":-9.752954,"marketCap":403763493},{"date":"2023-01-13","current":-5.706058,"twenty":-18.104257,"median":-12.846213,"eighty":-7.688928,"marketCap":305441169},{"date":"2023-01-20","current":-6.459312,"twenty":-17.9977,"median":-12.837332,"eighty":-7.374204,"marketCap":346324335},{"date":"2023-01-27","current":-5.951135,"twenty":-17.857094,"median":-12.821298,"eighty":-6.862976,"marketCap":319632020},{"date":"2023-02-03","current":-5.776873,"twenty":-17.539987,"median":-12.756949,"eighty":-6.367933,"marketCap":310171453},{"date":"2023-02-10","current":-6.06212,"twenty":-17.052096,"median":-12.693639,"eighty":-6.243368,"marketCap":320307775},{"date":"2023-02-17","current":-5.565251,"twenty":-16.755938,"median":-12.64181,"eighty":-6.151395,"marketCap":293615460},{"date":"2023-02-24","current":-5.080906,"twenty":-16.600297,"median":-12.612561,"eighty":-6.08797,"marketCap":265233759},{"date":"2023-03-03","current":-5.604926,"twenty":-16.439572,"median":-12.581052,"eighty":-6.019199,"marketCap":293953338},{"date":"2023-03-10","current":-4.059398,"twenty":-16.126823,"median":-12.554737,"eighty":-5.957727,"marketCap":214214271},{"date":"2023-03-17","current":-4.759844,"twenty":-15.898426,"median":-12.5386,"eighty":-5.915214,"marketCap":251042908},{"date":"2023-03-24","current":-4.748457,"twenty":-15.814998,"median":-12.484354,"eighty":-5.839251,"marketCap":252732295},{"date":"2023-03-31","current":-5.062872,"twenty":-15.558556,"median":-12.41617,"eighty":-5.818726,"marketCap":272160245},{"date":"2023-04-06","current":-5.515395,"twenty":-15.2868,"median":-12.393076,"eighty":-5.798276,"marketCap":298007866},{"date":"2023-04-14","current":-3.407139,"twenty":-15.104598,"median":-12.376683,"eighty":-5.751686,"marketCap":287439901},{"date":"2023-04-21","current":-3.423024,"twenty":-15.075219,"median":-12.365371,"eighty":-5.695738,"marketCap":286594490},{"date":"2023-04-28","current":-3.621546,"twenty":-14.971826,"median":-12.310085,"eighty":-5.661512,"marketCap":304686295},{"date":"2023-05-05","current":-3.635585,"twenty":-14.858222,"median":-12.26867,"eighty":-5.593428,"marketCap":305362624},{"date":"2023-05-12","current":-3.330904,"twenty":-14.826016,"median":-12.249364,"eighty":-5.568587,"marketCap":277633128},{"date":"2023-05-19","current":-3.332274,"twenty":-14.818952,"median":-12.234113,"eighty":-5.5204,"marketCap":297584839},{"date":"2023-05-26","current":-3.231497,"twenty":-14.811441,"median":-12.222059,"eighty":-5.439393,"marketCap":287439901},{"date":"2023-06-02","current":-3.434585,"twenty":-14.791955,"median":-12.201472,"eighty":-5.312927,"marketCap":305832502},{"date":"2023-06-09","current":-3.407273,"twenty":-14.764775,"median":-12.198453,"eighty":-5.28475,"marketCap":304479261},{"date":"2023-06-16","current":-4.170938,"twenty":-14.740265,"median":-12.160354,"eighty":-5.07843,"marketCap":377892593},{"date":"2023-06-23","current":-4.359744,"twenty":-14.731325,"median":-12.152393,"eighty":-5.057591,"marketCap":396297439},{"date":"2023-06-30","current":-7.00064,"twenty":-14.718305,"median":-12.136009,"eighty":-5.055831,"marketCap":632126719},{"date":"2023-07-07","current":-7.084548,"twenty":-14.696694,"median":-12.097209,"eighty":-5.062872,"marketCap":638244074},{"date":"2023-07-14","current":-6.875228,"twenty":-14.6624,"median":-12.079819,"eighty":-5.068525,"marketCap":638244074},{"date":"2023-07-21","current":-7.028003,"twenty":-14.653302,"median":-12.064139,"eighty":-5.080906,"marketCap":649663138},{"date":"2023-07-28","current":-7.498848,"twenty":-14.622905,"median":-12.04158,"eighty":-5.207419,"marketCap":683512504},{"date":"2023-08-04","current":-7.953511,"twenty":-14.601036,"median":-12.024634,"eighty":-5.228713,"marketCap":722255754},{"date":"2023-08-11","current":-7.354477,"twenty":-14.583407,"median":-11.998532,"eighty":-5.261383,"marketCap":747059362},{"date":"2023-08-18","current":-7.862758,"twenty":-14.572779,"median":-11.956319,"eighty":-5.28475,"marketCap":788698737},{"date":"2023-08-25","current":-7.637624,"twenty":-14.506463,"median":-11.943194,"eighty":-5.298861,"marketCap":762796904},{"date":"2023-08-31","current":-8.133422,"twenty":-14.4867,"median":-11.921598,"eighty":-5.305964,"marketCap":813459365},{"date":"2023-09-08","current":-7.866907,"twenty":-14.484166,"median":-11.909309,"eighty":-5.312927,"marketCap":776279656},{"date":"2023-09-15","current":-8.565073,"twenty":-14.483879,"median":-11.869315,"eighty":-5.324599,"marketCap":842467710},{"date":"2023-09-22","current":-8.218785,"twenty":-14.422991,"median":-11.843691,"eighty":-5.364732,"marketCap":808147978},{"date":"2023-09-29","current":-8.499622,"twenty":-14.407261,"median":-11.810464,"eighty":-5.391254,"marketCap":828167822},{"date":"2023-10-06","current":-8.075664,"twenty":-14.404891,"median":-11.805298,"eighty":-5.421144,"marketCap":784042452},{"date":"2023-10-13","current":-7.97887,"twenty":-14.393189,"median":-11.762441,"eighty":-5.494747,"marketCap":776279656},{"date":"2023-10-20","current":-7.871535,"twenty":-14.374592,"median":-11.67635,"eighty":-5.497417,"marketCap":767699722},{"date":"2023-10-27","current":-7.699507,"twenty":-14.37054,"median":-11.628617,"eighty":-5.497654,"marketCap":747679879},{"date":"2023-11-03","current":-7.17043,"twenty":-14.351862,"median":-11.573402,"eighty":-5.505177,"marketCap":701920236},{"date":"2023-11-10","current":-5.970942,"twenty":-14.325681,"median":-11.546094,"eighty":-5.518658,"marketCap":686476556},{"date":"2023-11-17","current":-5.487665,"twenty":-14.300392,"median":-11.499199,"eighty":-5.518658,"marketCap":639755166},{"date":"2023-11-24","current":-5.931936,"twenty":-14.283081,"median":-11.456561,"eighty":-5.501771,"marketCap":694263454},{"date":"2023-12-01","current":-6.025826,"twenty":-14.216157,"median":-11.367098,"eighty":-5.517027,"marketCap":705329046},{"date":"2023-12-08","current":-11.439876,"twenty":-14.20757,"median":-11.347894,"eighty":-5.524424,"marketCap":1324602518},{"date":"2023-12-15","current":-11.41059,"twenty":-14.202076,"median":-11.375314,"eighty":-5.532271,"marketCap":1346488162},{"date":"2023-12-22","current":-11.925452,"twenty":-14.184853,"median":-11.42744,"eighty":-5.551316,"marketCap":1406934225},{"date":"2023-12-29","current":-12.247032,"twenty":-14.141201,"median":-11.449501,"eighty":-5.556079,"marketCap":1455916379},{"date":"2024-01-05","current":-11.217845,"twenty":-14.124263,"median":-11.444688,"eighty":-5.560701,"marketCap":1319391651},{"date":"2024-01-12","current":-13.194311,"twenty":-14.118795,"median":-11.460366,"eighty":-5.568587,"marketCap":1550325393},{"date":"2024-01-19","current":-14.465426,"twenty":-14.174814,"median":-11.47464,"eighty":-5.574125,"marketCap":1686754028},{"date":"2024-01-26","current":-14.983944,"twenty":-14.20757,"median":-11.499199,"eighty":-5.577066,"marketCap":1742861042},{"date":"2024-02-02","current":-15.192524,"twenty":-14.300739,"median":-11.528223,"eighty":-5.581389,"marketCap":1768847449},{"date":"2024-02-09","current":-14.748842,"twenty":-14.393189,"median":-11.54682,"eighty":-5.589596,"marketCap":1703881432},{"date":"2024-02-16","current":-13.65194,"twenty":-14.404891,"median":-11.567624,"eighty":-5.608959,"marketCap":1576311800},{"date":"2024-02-23","current":-14.13304,"twenty":-14.396825,"median":-11.581834,"eighty":-5.625092,"marketCap":1640687216},{"date":"2024-03-01","current":-10.303743,"twenty":-14.378644,"median":-11.573402,"eighty":-5.629721,"marketCap":1195373004},{"date":"2024-03-08","current":-12.093153,"twenty":-14.358385,"median":-11.567624,"eighty":-5.636181,"marketCap":1418455194},{"date":"2024-03-15","current":-10.896325,"twenty":-14.342077,"median":-11.552539,"eighty":-5.658684,"marketCap":1273758779},{"date":"2024-03-22","current":-11.538805,"twenty":-14.301086,"median":-11.546205,"eighty":-5.665753,"marketCap":1344762225},{"date":"2024-03-28","current":-10.904189,"twenty":-14.299698,"median":-11.538805,"eighty":-5.674035,"marketCap":1264076491},{"date":"2024-04-05","current":-10.349243,"twenty":-14.288877,"median":-11.507756,"eighty":-5.680711,"marketCap":1206520668},{"date":"2024-04-12","current":-11.107813,"twenty":-14.231653,"median":-11.490879,"eighty":-5.687459,"marketCap":1200065809},{"date":"2024-04-19","current":-9.215802,"twenty":-14.210621,"median":-11.46913,"eighty":-5.702618,"marketCap":991303742},{"date":"2024-04-26","current":-11.339937,"twenty":-14.20395,"median":-11.459096,"eighty":-5.715476,"marketCap":1225406418},{"date":"2024-05-03","current":-11.733497,"twenty":-14.200071,"median":-11.46913,"eighty":-5.724599,"marketCap":1266307115},{"date":"2024-05-10","current":-9.668623,"twenty":-14.189365,"median":-11.459096,"eighty":-5.733174,"marketCap":1107009662},{"date":"2024-05-17","current":-10.115404,"twenty":-14.156013,"median":-11.42744,"eighty":-5.759289,"marketCap":1168360708},{"date":"2024-05-24","current":-9.147602,"twenty":-14.136092,"median":-11.375314,"eighty":-5.774576,"marketCap":1052116621},{"date":"2024-05-31","current":-8.827191,"twenty":-14.129207,"median":-11.35501,"eighty":-5.782121,"marketCap":1017135762},{"date":"2024-06-07","current":-7.823819,"twenty":-14.123069,"median":-11.339823,"eighty":-5.787829,"marketCap":904658844},{"date":"2024-06-14","current":-8.515887,"twenty":-14.119026,"median":-11.316994,"eighty":-5.792437,"marketCap":974082396},{"date":"2024-06-21","current":-8.52603,"twenty":-14.116428,"median":-11.288753,"eighty":-5.797709,"marketCap":970853394},{"date":"2024-06-28","current":-8.52006,"twenty":-14.116197,"median":-11.262481,"eighty":-5.798843,"marketCap":969238893},{"date":"2024-07-05","current":-7.963908,"twenty":-14.11303,"median":-11.251924,"eighty":-5.805313,"marketCap":914884019},{"date":"2024-07-12","current":-8.497692,"twenty":-14.104041,"median":-11.224936,"eighty":-5.814579,"marketCap":981616735},{"date":"2024-07-15","current":-8.709438,"twenty":-14.101747,"median":-11.224715,"eighty":-5.815211,"marketCap":1010139590},{"date":"2024-08-02","current":-7.485095,"twenty":-14.099454,"median":-11.224493,"eighty":-5.815842,"marketCap":857838309},{"date":"2024-08-09","current":-7.640912,"twenty":-14.094802,"median":-11.205504,"eighty":-5.819476,"marketCap":885822997},{"date":"2024-08-16","current":-8.240501,"twenty":-14.093907,"median":-11.162588,"eighty":-5.823431,"marketCap":1032742607},{"date":"2024-08-23","current":-7.760367,"twenty":-14.048436,"median":-11.118035,"eighty":-5.826337,"marketCap":983480417},{"date":"2024-08-30","current":-7.393035,"twenty":-14.034683,"median":-11.087899,"eighty":-5.833183,"marketCap":934333400},{"date":"2024-09-06","current":-8.155019,"twenty":-14.033224,"median":-11.020127,"eighty":-5.839251,"marketCap":1031547280},{"date":"2024-09-13","current":-8.802104,"twenty":-14.027088,"median":-10.978779,"eighty":-5.849019,"marketCap":1108238229},{"date":"2024-09-20","current":-8.962749,"twenty":-13.99324,"median":-10.957045,"eighty":-5.877056,"marketCap":1139022624},{"date":"2024-09-27","current":-8.000083,"twenty":-13.961974,"median":-10.894902,"eighty":-5.894802,"marketCap":1020205660},{"date":"2024-10-04","current":-7.688355,"twenty":-13.947654,"median":-10.874176,"eighty":-5.909483,"marketCap":966197949},{"date":"2024-10-11","current":-7.725025,"twenty":-13.936046,"median":-10.812773,"eighty":-5.924083,"marketCap":962957487},{"date":"2024-10-18","current":-9.289256,"twenty":-13.925882,"median":-10.792815,"eighty":-5.928401,"marketCap":1147663858},{"date":"2024-10-25","current":-9.347449,"twenty":-13.904362,"median":-10.773913,"eighty":-5.930655,"marketCap":1151984475},{"date":"2024-10-31","current":-10.81176,"twenty":-13.888979,"median":-10.69668,"eighty":-5.935928,"marketCap":1339391232},{"date":"2024-11-08","current":-9.795031,"twenty":-13.882336,"median":-10.614452,"eighty":-5.945603,"marketCap":1205452109},{"date":"2024-11-15","current":-7.934741,"twenty":-13.880109,"median":-10.567811,"eighty":-5.951569,"marketCap":1109858461},{"date":"2024-11-22","current":-8.193559,"twenty":-13.878421,"median":-10.530141,"eighty":-5.955891,"marketCap":1136322239},{"date":"2024-11-29","current":-8.515548,"twenty":-13.874795,"median":-10.499116,"eighty":-5.962822,"marketCap":1187704999},{"date":"2024-12-06","current":-7.575701,"twenty":-13.869107,"median":-10.430822,"eighty":-5.969,"marketCap":1058630209},{"date":"2024-12-13","current":-7.438607,"twenty":-13.864864,"median":-10.405945,"eighty":-5.972,"marketCap":1031513657},{"date":"2024-12-20","current":-7.511117,"twenty":-13.847086,"median":-10.370165,"eighty":-5.976517,"marketCap":1030971326},{"date":"2024-12-27","current":-7.680726,"twenty":-13.801742,"median":-10.357252,"eighty":-5.977661,"marketCap":1057545547},{"date":"2025-01-03","current":-7.415916,"twenty":-13.792864,"median":-10.345951,"eighty":-6.00833,"marketCap":1005481766},{"date":"2025-01-10","current":-7.387777,"twenty":-13.788234,"median":-10.323543,"eighty":-6.019199,"marketCap":1005481766},{"date":"2025-01-17","current":-6.953437,"twenty":-13.781733,"median":-10.297117,"eighty":-6.023626,"marketCap":946367682},{"date":"2025-01-24","current":-7.612205,"twenty":-13.774759,"median":-10.284647,"eighty":-6.025423,"marketCap":1047783588},{"date":"2025-01-31","current":-6.977006,"twenty":-13.765434,"median":-10.25901,"eighty":-6.034301,"marketCap":961552951},{"date":"2025-02-07","current":-7.219276,"twenty":-13.753463,"median":-10.232674,"eighty":-6.052543,"marketCap":990296497},{"date":"2025-02-14","current":-6.822516,"twenty":-13.740454,"median":-10.115609,"eighty":-6.061351,"marketCap":942029033},{"date":"2025-02-21","current":-6.467941,"twenty":-13.734308,"median":-10.093087,"eighty":-6.062421,"marketCap":894846232},{"date":"2025-02-28","current":-6.133931,"twenty":-13.727465,"median":-10.02417,"eighty":-6.065143,"marketCap":843867113},{"date":"2025-03-07","current":-5.852269,"twenty":-13.71316,"median":-9.970579,"eighty":-6.049778,"marketCap":837901472},{"date":"2025-03-14","current":-6.385184,"twenty":-13.708332,"median":-9.910974,"eighty":-6.026825,"marketCap":917081805},{"date":"2025-03-21","current":-5.844642,"twenty":-13.700767,"median":-9.829627,"eighty":-6.025288,"marketCap":838443803},{"date":"2025-03-28","current":-5.916884,"twenty":-13.679442,"median":-9.795031,"eighty":-5.984934,"marketCap":844409444},{"date":"2025-04-04","current":-5.41793,"twenty":-13.665275,"median":-9.712775,"eighty":-5.969,"marketCap":792887995},{"date":"2025-04-11","current":-4.319691,"twenty":-13.654878,"median":-9.636637,"eighty":-5.953745,"marketCap":648468389},{"date":"2025-04-17","current":-4.898467,"twenty":-13.65194,"median":-9.603412,"eighty":-5.931936,"marketCap":747645908},{"date":"2025-04-25","current":-5.660159,"twenty":-13.648303,"median":-9.484661,"eighty":-5.916884,"marketCap":862626437},{"date":"2025-05-02","current":-6.426634,"twenty":-13.611466,"median":-9.396394,"eighty":-5.918352,"marketCap":972702584},{"date":"2025-05-09","current":-6.135697,"twenty":-13.604729,"median":-9.345786,"eighty":-5.927903,"marketCap":928563139},{"date":"2025-05-16","current":-5.081075,"twenty":-13.598948,"median":-9.280564,"eighty":-5.916884,"marketCap":866985889},{"date":"2025-05-23","current":-5.189286,"twenty":-13.570194,"median":-9.208581,"eighty":-5.882056,"marketCap":893142597},{"date":"2025-05-30","current":-5.256736,"twenty":-13.527456,"median":-9.173722,"eighty":-5.851134,"marketCap":911125334},{"date":"2025-06-06","current":-5.007101,"twenty":-13.509055,"median":-9.060878,"eighty":-5.837961,"marketCap":874614929},{"date":"2025-06-13","current":-5.317982,"twenty":-13.49872,"median":-8.982791,"eighty":-5.819476,"marketCap":938916836},{"date":"2025-06-20","current":-5.183436,"twenty":-13.485895,"median":-8.943559,"eighty":-5.800161,"marketCap":906765882},{"date":"2025-06-27","current":-5.465947,"twenty":-13.472919,"median":-8.879507,"eighty":-5.782121,"marketCap":975427241},{"date":"2025-07-03","current":-5.649134,"twenty":-13.4687,"median":-8.851321,"eighty":-5.729733,"marketCap":1013572441},{"date":"2025-07-11","current":-6.060959,"twenty":-13.466131,"median":-8.823918,"eighty":-5.695738,"marketCap":1080599005},{"date":"2025-07-18","current":-7.314861,"twenty":-13.46266,"median":-8.816193,"eighty":-5.710767,"marketCap":1293122259},{"date":"2025-07-25","current":-7.006501,"twenty":-13.460198,"median":-8.785147,"eighty":-5.721214,"marketCap":1257999997},{"date":"2025-08-01","current":-8.237689,"twenty":-13.451559,"median":-8.722056,"eighty":-5.729733,"marketCap":1437436162},{"date":"2025-08-08","current":-8.281316,"twenty":-13.442628,"median":-8.688191,"eighty":-5.747092,"marketCap":1469250645},{"date":"2025-08-15","current":-8.47781,"twenty":-13.428755,"median":-8.660023,"eighty":-5.769982,"marketCap":1662306709},{"date":"2025-08-22","current":-8.638654,"twenty":-13.403956,"median":-8.63053,"eighty":-5.780372,"marketCap":1688336740},{"date":"2025-08-29","current":-8.414646,"twenty":-13.396944,"median":-8.638654,"eighty":-5.787092,"marketCap":1651460863},{"date":"2025-09-05","current":-8.112917,"twenty":-13.396458,"median":-8.622065,"eighty":-5.790869,"marketCap":1589278011},{"date":"2025-09-12","current":-8.597222,"twenty":-13.393909,"median":-8.60362,"eighty":-5.797709,"marketCap":1699182587},{"date":"2025-09-19","current":-8.94501,"twenty":-13.385494,"median":-8.610019,"eighty":-5.800038,"marketCap":1774380454},{"date":"2025-09-26","current":-9.045131,"twenty":-13.370479,"median":-8.627645,"eighty":-5.80289,"marketCap":1777272680},{"date":"2025-10-03","current":-8.512022,"twenty":-13.360301,"median":-8.638654,"eighty":-5.813948,"marketCap":1676044781},{"date":"2025-10-10","current":-8.486281,"twenty":-13.357847,"median":-8.622235,"eighty":-5.817225,"marketCap":1651460863},{"date":"2025-10-17","current":-8.047023,"twenty":-13.353429,"median":-8.597222,"eighty":-5.821028,"marketCap":1580601334},{"date":"2025-10-24","current":-8.513119,"twenty":-13.347233,"median":-8.60362,"eighty":-5.824758,"marketCap":1663029766},{"date":"2025-10-31","current":-8.263348,"twenty":-13.342738,"median":-8.57038,"eighty":-5.828443,"marketCap":1608077478},{"date":"2025-11-07","current":-8.118597,"twenty":-13.33536,"median":-8.561701,"eighty":-5.835563,"marketCap":1576262995},{"date":"2025-11-14","current":-8.953433,"twenty":-13.315064,"median":-8.562935,"eighty":-5.839457,"marketCap":1754134874},{"date":"2025-11-21","current":-8.32101,"twenty":-13.306363,"median":-8.564004,"eighty":-5.842723,"marketCap":1572018786},{"date":"2025-11-28","current":-9.70873,"twenty":-13.305926,"median":-8.567726,"eighty":-5.844642,"marketCap":1843549304},{"date":"2025-12-05","current":-9.421046,"twenty":-13.303031,"median":-8.581097,"eighty":-5.846596,"marketCap":1798727281},{"date":"2025-12-12","current":-8.095034,"twenty":-13.295471,"median":-8.575738,"eighty":-5.852269,"marketCap":1557727706},{"date":"2025-12-19","current":-8.116161,"twenty":-13.29424,"median":-8.562935,"eighty":-5.853536,"marketCap":1560326085},{"date":"2025-12-26","current":-8.732727,"twenty":-13.291734,"median":-8.57038,"eighty":-5.866198,"marketCap":1684398642},{"date":"2026-01-02","current":-9.374295,"twenty":-13.28902,"median":-8.597222,"eighty":-5.876979,"marketCap":1802624848},{"date":"2026-01-09","current":-8.51177,"twenty":-13.280164,"median":-8.575738,"eighty":-5.882433,"marketCap":1623986350},{"date":"2026-01-16","current":-8.766662,"twenty":-13.272619,"median":-8.610019,"eighty":-5.888715,"marketCap":1666209995},{"date":"2026-01-23","current":-9.448662,"twenty":-13.268752,"median":-8.622065,"eighty":-5.894114,"marketCap":1817565522},{"date":"2026-01-30","current":-9.241158,"twenty":-13.264633,"median":-8.634183,"eighty":-5.904462,"marketCap":1805223226},{"date":"2026-02-06","current":-8.459688,"twenty":-13.260074,"median":-8.637068,"eighty":-5.918058,"marketCap":1633080673},{"date":"2026-02-13","current":-8.89399,"twenty":-13.217763,"median":-8.637068,"eighty":-5.918058,"marketCap":1727921476},{"date":"2026-02-20","current":-9.442084,"twenty":-13.195802,"median":-8.637068,"eighty":-5.918058,"marketCap":1818864712},{"date":"2026-02-27","current":-9.418754,"twenty":-13.077142,"median":-8.637068,"eighty":-5.918058,"marketCap":1818864712},{"date":"2026-03-06","current":-8.866459,"twenty":-13.050618,"median":-8.637068,"eighty":-5.918058,"marketCap":1678552291},{"date":"2026-03-13","current":-9.080009,"twenty":-12.99028,"median":-8.637068,"eighty":-5.918058,"marketCap":1713630396},{"date":"2026-03-20","current":-8.989812,"twenty":-12.872607,"median":-8.637068,"eighty":-5.918058,"marketCap":1697390533},{"date":"2026-03-27","current":-9.422218,"twenty":-12.835328,"median":-8.637068,"eighty":-5.918058,"marketCap":1779239445},{"date":"2026-04-02","current":-10.121514,"twenty":-12.76463,"median":-8.637068,"eighty":-5.918058,"marketCap":1913055920},{"date":"2026-04-10","current":-8.614145,"twenty":-12.646197,"median":-8.634183,"eighty":-5.918058,"marketCap":1770589741},{"date":"2026-04-17","current":-9.098299,"twenty":-12.580967,"median":-8.627645,"eighty":-5.918058,"marketCap":1882437117},{"date":"2026-04-24","current":-8.672978,"twenty":-12.531366,"median":-8.627645,"eighty":-5.918058,"marketCap":1784979462},{"date":"2026-05-01","current":-9.840216,"twenty":-12.408666,"median":-8.627645,"eighty":-5.918058,"marketCap":2028296560},{"date":"2026-05-08","current":-9.387238,"twenty":-12.372989,"median":-8.627645,"eighty":-5.918058,"marketCap":1941304156},{"date":"2026-05-15","current":-10.205734,"twenty":-12.288471,"median":-8.627645,"eighty":-5.918058,"marketCap":2008020135},{"date":"2026-05-22","current":-10.228389,"twenty":-12.254036,"median":-8.627645,"eighty":-5.918058,"marketCap":1997554883},{"date":"2026-05-29","current":-10.59007,"twenty":-12.233824,"median":-8.622406,"eighty":-5.917765,"marketCap":2080240286},{"date":"2026-06-05","current":-11.245266,"twenty":-12.202715,"median":-8.627645,"eighty":-5.918058,"marketCap":2203549908},{"date":"2026-06-12","current":-11.54906,"twenty":-12.154142,"median":-8.627645,"eighty":-5.918058,"marketCap":2243259786},{"date":"2026-06-18","current":-12.068208,"twenty":-12.129758,"median":-8.627645,"eighty":-5.918058,"marketCap":2334681645},{"date":"2026-06-26","current":-12.126491,"twenty":-12.093842,"median":-8.622406,"eighty":-5.917765,"marketCap":2326994875},{"date":"2026-07-02","current":-12.298451,"twenty":-12.093842,"median":-8.622406,"eighty":-5.917765,"marketCap":2372416697},{"date":"2026-07-10","current":-13.041486,"twenty":-12.086912,"median":-8.622406,"eighty":-5.917765,"marketCap":2512874946},{"date":"2026-07-17","current":-12.197585,"twenty":-12.086912,"median":-8.622406,"eighty":-5.917765,"marketCap":2352151577},{"date":"2026-07-24","current":-12.127093,"twenty":-12.086912,"median":-8.622406,"eighty":-5.917765,"marketCap":2324199686},{"date":"2026-07-31","current":-12.200057,"twenty":-12.075175,"median":-8.622235,"eighty":-5.917471,"marketCap":2367525116},{"date":"2026-08-07","current":-12.393886,"twenty":-12.081578,"median":-8.622235,"eighty":-5.917471,"marketCap":2407356560},{"date":"2026-08-14","current":-12.119292,"twenty":-12.094187,"median":-8.622235,"eighty":-5.917471,"marketCap":2389761384},{"date":"2026-08-21","current":-12.797528,"twenty":-12.094187,"median":-8.622235,"eighty":-5.917471,"marketCap":2554741973}],"updateTime":1787624669808},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PHVS\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620266092","title":"Pharvaris NV director Elisabeth Bjork files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620266092","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620266092?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:24","pubTimestamp":1773858253,"startTime":"0","endTime":"0","summary":"Pharvaris reported an initial statement of beneficial ownership for director Elisabeth Bjork. Bjork reported direct ownership of 15,167 shares of common stock. She also reported stock options covering 16,500 shares with an exercise price of USD 28. Bjork also reported stock options covering 15,000 shares with an exercise price of USD 16.05.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLj2h6x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620266041","title":"Pharvaris NV CFO and CLO David W. Nassif files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620266041","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620266041?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:24","pubTimestamp":1773858252,"startTime":"0","endTime":"0","summary":"Pharvaris reported that David Nassif, its CFO and CLO, filed an initial statement of beneficial ownership. The filing reported 123,925 shares of common stock beneficially owned directly. It also reported stock options to buy 60,000 shares at USD 28 and 230,000 shares at USD 20.15.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLp77Sy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620266099","title":"Pharvaris NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Lu Peng","url":"https://stock-news.laohu8.com/highlight/detail?id=2620266099","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620266099?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:24","pubTimestamp":1773858248,"startTime":"0","endTime":"0","summary":"Pharvaris reported an initial statement of beneficial ownership for Peng Lu, its chief medical officer. The filing shows direct beneficial ownership of 66,309 shares of common stock. It also reports stock options covering 245,308 shares with an exercise price of USD 2.59. Additional stock options include 70,000 shares with an exercise price of USD 28.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9MBrdz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426609","title":"Pharvaris NV Director Viviane Monges Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426609","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426609?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:24","pubTimestamp":1773858243,"startTime":"0","endTime":"0","summary":"Viviane Monges, a director at Pharvaris, filed an initial statement of beneficial ownership dated March 17, 2026. The filing reported 14,654 shares of common stock beneficially owned directly. It also reported stock options for 119,000 shares of common stock, with exercise prices ranging from USD 8.05 to USD 28.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLDNT73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620126601","title":"Pharvaris NV CEO Berndt Modig files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620126601","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620126601?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:24","pubTimestamp":1773858240,"startTime":"0","endTime":"0","summary":"Berndt Modig, chief executive officer and a director of Pharvaris, filed an initial statement of beneficial ownership dated March 17, 2026. The filing reported 165,417 shares of common stock held directly. It also reported 950,000 shares of common stock held indirectly through Schoodic Management BV. The filing listed stock options covering 1.1 million shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9ngG6k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620643446","title":"Is New HAE Patient-Reported Outcome Study Altering The Investment Case For Pharvaris’ Deucrictibant (PHVS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620643446","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620643446?lang=en_us&edition=fundamental","pubTime":"2026-03-17 13:14","pubTimestamp":1773724454,"startTime":"0","endTime":"0","summary":"Pharvaris recently reported that a company-sponsored real-world, mixed methods study on patient experiences during acute hereditary angioedema (HAE) attacks and related clinical endpoints has been published in Clinical Reviews in Allergy & Immunology, supporting the use of several patient-reported outcome (PRO) tools in ongoing and future deucrictibant trials.\nThe study’s finding that patients view even small early improvements, captured by the End of Progression™ endpoint, as meaningfully...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-new-hae-patient-reported-outcome-study-altering-the-inves","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-new-hae-patient-reported-outcome-study-altering-the-inves","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PRO","LU1169590202.USD","IE0034390439.USD","IE00B19Z6F94.USD","BK4198","LU0205194284.USD","LU0205193047.USD","PHVS","BK4023","LU1169589451.USD","HAE","IE00B64QTZ34.USD","PRO.AU","BK4007","LU0106261612.USD","LU0012050646.USD","IE00BLDYK493.USD","BK7024"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619347463","title":"Pharvaris (PHVS) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2619347463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619347463?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:37","pubTimestamp":1773664647,"startTime":"0","endTime":"0","summary":"In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris, with a price target of $41.00. According to TipR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pharvaris-phvs-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pharvaris-phvs-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1162221912.USD","LU1244550494.USD","LU2111349929.HKD","LU0267386448.USD","LU0557290698.USD","LU0106831901.USD","LU0158827781.USD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU0882574139.USD","LU1244550577.SGD","LU0320765646.SGD","LU0106261372.USD","LU0158827948.USD","BK4534","LU1074936037.SGD","LU1363072403.SGD","LU1989772840.SGD","LU1791710400.SGD","LU0234570918.USD","LU2347655156.SGD","LU1732799900.SGD","LU0006306889.USD","BK4516","BK4504","LU1720051017.SGD","LU2271345857.HKD","BK4588","LU1732800096.USD","BK4585","LU0098860793.USD","LU0225283273.USD","LU1720051108.HKD","LU2028103732.USD","LU2133065610.SGD","LU0314104364.USD","LU1668664300.SGD","LU1791710582.SGD","LU2357305700.SGD","LU2089283258.USD","LU0795875169.SGD","LU1244550221.USD","LU2089284900.SGD","LU0528227936.USD","LU0912757837.SGD","BK4127","LU0795875086.SGD","PHVS","BK4581","LU2023251221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618525949","title":"Pharvaris reports results from study of patient experience during HAE attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2618525949","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618525949?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:55","pubTimestamp":1773226559,"startTime":"0","endTime":"0","summary":"Pharvaris (PHVS) announced that results from a Pharvaris-sponsored non-interventional, mixed methods, real-world study assessing the patient experi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharvaris-reports-results-from-study-of-patient-experience-during-hae-attacks-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharvaris-reports-results-from-study-of-patient-experience-during-hae-attacks-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0012050646.USD","HAE","LU0106261612.USD","IE00B19Z6F94.USD","IE00BLDYK493.USD","LU1169589451.USD","LU1169590202.USD","LU0205194284.USD","BK4007","PHVS","LU0205193047.USD","IE00B64QTZ34.USD","BK4198","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618946254","title":"Pharvaris real-world study validates PGI and AMRA patient-reported outcome measures for acute HAE attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2618946254","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618946254?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:50","pubTimestamp":1773226225,"startTime":"0","endTime":"0","summary":"Pharvaris reported that results from a sponsor-led, non-interventional mixed-methods real-world study on patient-reported outcomes during acute hereditary angioedema  attacks were published in Clinical Reviews in Allergy & Immunology. The study evaluated the Patient Global Impression  and Angioedema syMptom Rating scAle instruments  using real-time electronic assessments during attacks and post-attack interviews. Pharvaris said the analyses supported an endpoint sequence of End of Progression, followed by symptom relief and then symptom resolution. The company said the findings informed the prespecified endpoint hierarchy for its Phase 3 RAPIDe-3 on-demand HAE trial of deucrictibant . These results have already been presented in the form of a journal publication.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL8JLyQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","PHVS","LU2210150020.SGD","LU2095319765.USD","BK4007","LU2210149790.SGD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","SG9999014039.USD","SG9999014021.USD","IE00BGHQF748.EUR","BK4585","IE00B3QW5Z07.USD","BK4112","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618931961","title":"Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618931961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618931961?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:36","pubTimestamp":1773138971,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris yesterday and set a price target of $41.00. The company’s shares closed ye...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-pharvaris-phvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-pharvaris-phvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618060492","title":"Can Pharvaris (PHVS) Turn Deucrictibant’s Phase 2 Extension Data Into a Durable Franchise Advantage?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618060492","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618060492?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:35","pubTimestamp":1773102947,"startTime":"0","endTime":"0","summary":"Pharvaris N.V. recently reported final results from the open-label extension of its Phase 2 CHAPTER-1 trial of oral deucrictibant for hereditary angioedema, highlighting up to three years of improved quality of life, disease control, and treatment satisfaction, and reiterated plans to file an NDA for on-demand treatment in the first half of 2026.\nThe data underline how an oral bradykinin B2 receptor antagonist could reshape long-term management of bradykinin-mediated angioedema, potentially...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/can-pharvaris-phvs-turn-deucrictibants-phase-2-extension-dat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/can-pharvaris-phvs-turn-deucrictibants-phase-2-extension-dat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618627272","title":"Pharvaris' Deucrictibant Presents Opportunity in Hereditary Angioedema Market, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627272","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618627272?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:06","pubTimestamp":1773068816,"startTime":"0","endTime":"0","summary":"Pharvaris  could gain a position in the hereditary angioedema treatment market with its oral drug candidate deucrictibant, supported by clinical data and upcoming milestones, RBC Capital Markets said in a note Monday.The firm said data from a phase 3 study of deucrictibant's immediate-release formulation presents it \"as potentially the most effective oral drug in the on-demand treatment of hereditary angioedema attacks.\"RBC expects the company to submit a new drug application for the immediate-release formulation in H1, with a potential launch in 2027.The firm also said the drug's extended-release version, which is being evaluated for preventive treatment of HAE in a phase 3 trial, could disrupt the prophylaxis market.RBC said the combination of potential on-demand and preventive uses for deucrictibant could lead to Pharvaris capturing market share if development programs are successful.RBC initiated coverage of Pharvaris with an outperform rating and a $52 price target.Price: 26.21, C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618427766","title":"RBC Initiates Pharvaris at Outperform, Speculative Risk With $52 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2618427766","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618427766?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:19","pubTimestamp":1773051548,"startTime":"0","endTime":"0","summary":"Pharvaris (PHVS) has an average rating of buy and mean price target of $46.04, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616832064","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pharvaris (PHVS) and Cryo-Cell International (CCEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616832064","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616832064?lang=en_us&edition=fundamental","pubTime":"2026-03-04 01:00","pubTimestamp":1772557250,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pharvaris (PHVS – Research Report) and Cryo-Cell I...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-pharvaris-phvs-and-cryo-cell-international-ccel-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-pharvaris-phvs-and-cryo-cell-international-ccel-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XLV","XBI","BK4585","LU0029874061.USD","BK4196","BK4581","BK4137","BK4007","LU0128526141.USD","CCEL","PHVS","HCSG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616276263","title":"Pharvaris Price Target Maintained With a $60.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616276263","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616276263?lang=en_us&edition=fundamental","pubTime":"2026-03-04 00:58","pubTimestamp":1772557080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 11:58 ET (16:58 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616329691","title":"Pharvaris (PHVS) Valuation Check After Positive Deucrictibant Phase 2 And RAPIDe 3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2616329691","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616329691?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:27","pubTimestamp":1772548065,"startTime":"0","endTime":"0","summary":"Pharvaris (NasdaqGS:PHVS) is back in focus after releasing final Phase 2 CHAPTER-1 open-label extension data and detailed RAPIDe-3 results for deucrictibant in hereditary angioedema, underscoring fresh clinical evidence around both prophylactic and on-demand use.\nSee our latest analysis for Pharvaris.\nThe latest deucrictibant data arrives after a powerful run in Pharvaris’ total shareholder return, with an 82.77% 1 year gain and a very large 3 year payoff. The recent 90 day share price return...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-valuation-check-after-positive-deucrictibant","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-valuation-check-after-positive-deucrictibant","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616833961","title":"Pharvaris reports Phase 3 RAPIDe-3 success for deucrictibant in hereditary angioedema attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2616833961","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616833961?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:50","pubTimestamp":1772452215,"startTime":"0","endTime":"0","summary":"Pharvaris NV announced clinical data for deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema , highlighting results from the Phase 3 placebo-controlled RAPIDe-3 study and final long-term findings from the Phase 2 CHAPTER-1 open-label extension. The company said these results were presented at the American Academy of Allergy, Asthma & Immunology  2026 Annual Meeting, including RAPIDe-3 outcomes showing a median 1.28 hours to onset of symptom relief and 11.95 hours to complete symptom resolution versus placebo, and CHAPTER-1 data reporting a reduction in mean attack rate from 2.18 attacks/month at baseline to 0.12 attacks/month during the extension. Pharvaris also presented Phase 1 pharmacokinetic data supporting once-daily dosing of an extended-release deucrictibant tablet for prophylaxis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL1n8F9F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014039.USD","PHVS","IE00B64PRP62.GBP","BK4585","SG9999014013.SGD","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4112","BK4588","BK4007","IE00BKPKM429.USD","NDAQ","SG9999014005.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614877051","title":"BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614877051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614877051?lang=en_us&edition=fundamental","pubTime":"2026-02-25 14:30","pubTimestamp":1772001047,"startTime":"0","endTime":"0","summary":"BRAIN Biotech reported Q1 FY 2025/26 revenue of EUR 11.9 million, down 9.0%, with total operating performance of EUR 13.0 million. Adjusted EBITDA was EUR 0.3 million, while EBITDA was EUR -0.3 million and EBIT was EUR -1.5 million. Net loss for the period was EUR 2.9 million, with EPS  of EUR -0.13. In BRAINBiocatalysts, Q1 revenue was EUR 10.0 million  and adjusted EBITDA was EUR 0.5 million, with the company citing low sales momentum in baking enzymes and production interruptions tied to the relocation of production facilities to a new joint site in the Netherlands. BRAINBioIncubator Q1 revenue was EUR 1.9 million, supported by a EUR 1.0 million milestone payment related to the deucrictibant project; the company also noted that license and monetization agreements with Pharvaris and Royalty Pharma have generated EUR 3.3 million in milestone payments so far in FY 2025/26, including EUR 2.3 million received as cash inflow in Q1. Cash and cash equivalents were EUR 5.1 million at 31 Dece","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL5DmRdQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX","PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612450601","title":"Morgan Stanley Remains a Buy on Pharvaris (PHVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612450601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612450601?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:56","pubTimestamp":1771336606,"startTime":"0","endTime":"0","summary":"In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris, with a price target of $41.00. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-pharvaris-phvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-pharvaris-phvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2028103732.USD","LU2357305700.SGD","LU1791710582.SGD","LU0320765646.SGD","LU1363072403.SGD","LU0225283273.USD","IE00BKVL7J92.USD","BK4516","BK4007","LU0528227936.USD","LU1989772923.USD","LU1732800096.USD","LU0912757837.SGD","LU0098860793.USD","LU1720051017.SGD","LU1244550577.SGD","LU0158827781.USD","LU0106261372.USD","LU0882574139.USD","LU2347655156.SGD","BK4581","BK4585","LU0557290698.USD","LU1668664300.SGD","LU0267386448.USD","LU0971096721.USD","BK4534","LU0795875169.SGD","LU1791710400.SGD","LU0006306889.USD","IE00BZ1G4Q59.USD","LU1548497426.USD","LU1720051108.HKD","LU2271345857.HKD","PHVS","LU1074936037.SGD","BK4588","LU1989772840.SGD","LU0106831901.USD","LU0234570918.USD","LU2089284900.SGD","LU1732799900.SGD","LU2089283258.USD","BK4504","LU0314104364.USD","LU0158827948.USD","LU1162221912.USD","LU2133065610.SGD","LU1244550221.USD","BK4127"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":119,"code":"91000000","status":"200"}]}}